Background Somatic mutations have the potential to encode “non-self” immunogenic
antigens. We hypothesized that tumors with a large number of somatic mutations due to …

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of
human malignancies. Recent work from Le and colleagues strongly supports the use of …

Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by
hypermutation leading to abundant neoantigens that activate an antitumor immune …

Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the
United States. Despite excellent prognosis for early stage disease, 5-year survival rates in …

Immunotherapy with checkpoint inhibitors, such as the programmed death-1 (PD-1)
antibodies pembrolizumab and nivolumab, are effective in a variety of tumors, yet not all …

With the recent US Food and Drug Administration approvals of pembrolizumab and
nivolumab for refractory deficient mismatch repair metastatic colorectal cancer, immune …

PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that …

More than 1.6 million new cases of cancer will be diagnosed in the US in 2016, resulting in
more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in …

Background Several studies have evaluated the relationship between tumor mutational
burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 …